{
    "medicine_id": "1b1229070a318734c55e26b4ed3c38421cea006e",
    "platform_id": "DB05288",
    "metadata": {
        "name": "H big 180 U I Injection solution",
        "composition": "180 U I Anecortave acetate",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in glaucoma and macular degeneration",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00282",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Pamidronic acid"
                    },
                    {
                        "drugbank-id": "DB00399",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Zoledronic acid"
                    },
                    {
                        "drugbank-id": "DB00630",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00720",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Clodronic acid"
                    },
                    {
                        "drugbank-id": "DB00884",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Risedronic acid"
                    },
                    {
                        "drugbank-id": "DB01077",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Etidronic acid"
                    },
                    {
                        "drugbank-id": "DB01133",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Tiludronic acid"
                    },
                    {
                        "drugbank-id": "DB06255",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Incadronic acid"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}